As all pediatricians can attest, children are not just small adults. It's important to recognize that COVID-19 has a different disease course in pediatric patients and that COVID-19 can be severe.
What is the impact of antenatal corticosteroid treatment on risk for mental and behavioral disorders in offspring?
Antenatal corticosteroid treatment is standard care to mature a fetus when a preterm birth appears to be imminent. A new investigation looks at whether that exposure impacts the risk of mental and behavioral disorders in the offspring.
Researchers looked at a series of patients who had COVID-19 and multisystem inflammatory syndrome in children (MIS-C) and were admitted with cardiac involvement.
The US Food and Drug Administration (FDA) announced the approval of VESIcare LS for the treatment of neurogenic detrusor overactivity in children aged 2 years and older.
More acceptance of mental disorders can increase the likelihood of seeing treatment. An investigation looks at whether a curriculum could reduce the stigma surrounding mental illness in school.
An investigation looks at how the medical history of adolescent e-cigarette, or vaping, product use–associated lung injury (EVALI) differs from young adult and adult EVALI cases.
It was initially thought that children were primarily unaffected by COVID-19 and were asymptomatic carriers if they did have the disease. The rise of multisystem inflammatory syndrome in children (MIS-C) has radically changed this thinking.
The US Food and Drug Administration has approved dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years.
A new investigation looks at the safety of psoriasis treatment in pediatric cases.
Biomarkers can predict community-acquired pneumonia (CAP) severity in adults. A new study looks at whether they can do the same in pediatric cases.